Browse Locations ... - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Condition: Blepharoptosis
Intervention: Drug: RVL-1201
Sponsors: RevitaLid Inc.; RevitaLid Inc.
Recruiting - verified May 2013 - Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)Condition: Hepatitis C
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified May 2013 - Condition: Healthy
Interventions: Drug: 2x500 mg Metformin (Glumetza); Drug: 5 mg Linagliptin/1000 mg Metformin FDC; Drug: 5 mg Linagliptin (Tradjenta); Drug: 5 mg Linagliptin (Tradjenta); Drug: 3x500 mg Metformin (Glumetza); Drug: 5 mg Linagliptin (Tradjenta); Drug: 2 x 500 mg Metformin (Glumetza); Drug: 5 mg Linagliptin/1000mg Metformin FDC; Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified May 2013 - Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified April 2013 - Condition: Onychomycosis
Interventions: Drug: ME1111 solution; Drug: Vehicle Solution
Sponsors: Meiji Seika Pharma Co., Ltd.; Meiji Seika Pharma Co., Ltd.
Recruiting - verified May 2013 - Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Condition: Peripheral Arterial Disease
Interventions: Drug: edoxaban; Drug: Clopidogrel; Drug: Aspirin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; UMC Utrecht
Recruiting - verified March 2013 - Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Spasticity
Intervention: Drug: Baclofen
Sponsors: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries Limited
Recruiting - verified April 2013 - Conditions: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
Intervention: Drug: GS-9973
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Migraine
Intervention: Biological: ALD403
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2013 - Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Drug: tocilizumab
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Vancomycin inhalation powder; Drug: Placebo inhalation powder
Sponsors: Savara Inc.; Savara Inc.; Synteract, Inc.
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: BI 201335 (Faldaprevir); Drug: BI 201335 (Faldaprevir); Drug: BI 207127; Drug: BI 207127; Drug: Faldaprevir (BI 201335)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Drug: Plecanatide; Drug: Placebo
Sponsors: Synergy Pharmaceuticals, Inc.; Synergy Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127-placebo: 8-week treatment; Drug: Ribavirin: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Ribavirin-placebo: 8-week treatment; Drug: Faldaprevir-placebo: 8-week treatment; Drug: Faldaprevir: 16-week treatment; Drug: Ribavirin: 16-week treatment; Drug: RBV: 24-week treatment; Drug: BI 207127: 16-week treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: LY2940680; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified May 2013 - Condition: Diabetic Nephropathy
Interventions: Drug: PF-04634817; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: PF-05212377 (SAM-760); Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Tinea Pedis; Tinea Cruris
Interventions: Drug: NAFT500 (pediatric); Drug: NAFT600 (pediatric); Drug: NAFT500 (adult); Drug: NAFT600 (adult)
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013 - Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013 - Condition: Long QT Syndrome
Intervention:
Sponsors: Pediatrix Medical Group; Pediatrix Medical Group
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013 - Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: Aripiprazole IM Depot
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S; Otsuka America Pharmaceutical
Recruiting - verified May 2013 - Condition: Narcolepsy
Interventions: Drug: ADX-N05; Drug: Placebo
Sponsors: Aerial BioPharma, LLC; Aerial BioPharma, LLC
Recruiting - verified May 2013 - Condition: Infertility
Interventions: Drug: Gonal-f; Drug: AFOLIA
Sponsors: Finox AG; Finox AG
Not yet recruiting - verified April 2013 - Conditions: Obesity; Weight Gain; Eating Disorders
Interventions: Behavioral: Healthy Weight; Behavioral: Project Health
Sponsors: Oregon Research Institute; Oregon Research Institute
Recruiting - verified April 2013 - Condition: Paroxysmal Atrial Fibrillation (PAF)
Interventions: Device: Blazer Open-Irrigated Ablation Catheter (Boston Scientific); Device: FDA Approved Open-Irrigated Ablation Catheter
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: liraglutide; Drug: exenatide
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Schizophrenia
Intervention: Drug: Aripiprazole IM Depot
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S; Otsuka America Pharmaceutical
Recruiting - verified May 2013 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: LY2228820; Drug: Carboplatin; Drug: Placebo; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Acute Appendicitis
Intervention:
Sponsors: Venaxis, Inc.; Venaxis, Inc.
Recruiting - verified May 2013 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012 - Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy; Biological: Belimumab 10 mg/kg plus standard therapy; Drug: Standard therapy
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified December 2012 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant; Drug: BKM120; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Chronic Renal Failure Requiring Hemodialysis
Intervention: Biological: Epoetin Hospira
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Condition: Epilepsy
Intervention: Device: Cyberonics Investigational Accelerometry Device & Cyberonics Investigational Weighted Simulant Device
Sponsors: Cyberonics, Inc.; Cyberonics, Inc.
Recruiting - verified April 2013 - Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified April 2013 - Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Insulin lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Osteoarthritis of the Knee
Interventions: Drug: NKTR-181; Drug: Placebo
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: Asenapine; Drug: Placebo Asenapine; Drug: Olanzapine; Drug: Placebo Olanzapine
Sponsors: Merck; Merck
Recruiting - verified April 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: cUTI; Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either switch to oral therapy : 500 mg of Ciprofloxacin (oral); Drug: or switch to oral therapy : 800 mg/160 mg of sulfamethoxazole/trimethoprim
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Gastric Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified May 2013 - Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Anaemia
Interventions: Drug: GSK1278863; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; PPD
Recruiting - verified April 2013 - Condition: Age-Related Maculopathy
Interventions: Biological: RN6G; Biological: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Chronic Pain; Low Back Pain; Analgesia
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Bipolar I Disorder
Interventions: Drug: Intramuscular (IM) Depot Aripiprazole; Drug: Intramuscular (IM) Depot Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S
Recruiting - verified May 2013 - Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: 800 mg ibuprofen/26.6 mg famotidine
Sponsors: Horizon Pharma, Inc.; Horizon Pharma, Inc.; Pediatric Rheumatology Collaborative Study Group
Recruiting - verified April 2013 - Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified May 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Restless Legs Syndrome
Intervention: Drug: Rotigotine
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Condition: Restless Legs Syndrome
Intervention: Drug: Rotigotine
Sponsors: UCB, Inc.; UCB BIOSCIENCES, Inc.
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: 250 mg LX1033 tablets; Drug: Placebo tablet
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified April 2013 - Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Conditions: Chronic Renal Failure; Chronic Kidney Disease
Interventions: Biological: Epoetin Hospira; Biological: Epogen Amgen
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Neuropathic Pain
Interventions: Drug: SAR292833; Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Spasticity
Interventions: Drug: Baclofen ER Capsules; Drug: Placebo GRS
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013 - Condition: Paroxysmal Atrial Fibrillation
Interventions: Device: EAS-AC (HeartLight); Procedure: Control Arm Ablation
Sponsors: CardioFocus; CardioFocus
Recruiting - verified April 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013 - Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2013 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013 - Condition: Major Depressive Disorder With Mixed Features
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2013 - Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: OPC-34712
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Acute Schizophrenia
Interventions: Drug: OPC-34712; Drug: OPC-34712; Drug: OPC-34712; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Acute Schizophrenia
Interventions: Drug: Dose 3; Drug: Dose 2; Drug: Dose 1; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Biological: PF-04236921; Biological: PF-04236921
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2013 - Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013 - Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerConditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013 - Condition: Growth
Interventions: Other: Extensively hydrolyzed whey infant formula; Other: Extensively hydrolyzed casein infant formula
Sponsors: Nestlé; Nestlé
Recruiting - verified May 2013 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207217; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013 - Condition: Thromboembolism
Interventions: Drug: Coumadin; Drug: Coumadin; Drug: Coumadin
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation; University of Kansas; California Pacific Medical Center; Stanford University; Case Western Reserve University; Southlake Regional Health Centre; Catholic University, Italy
Recruiting - verified May 2013 - Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013 - Condition: Degenerative Disc Disease (DDD)
Interventions: Device: FLD; Device: Control
Sponsors: AxioMed Spine Corporation; AxioMed Spine Corporation
Recruiting - verified May 2013 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified April 2013 - Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified April 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013
 |
Find Paid Research Studies in Austin, Texas |
Clinical Trial Locations 